The JNK Inhibitor XG-102 Protects from Ischemic Damage with Delayed Intravenous Administration Also in the Presence of Recombinant Tissue Plasminogen Activator
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: XG-102 (formerly D-JNKI1), a TAT-coupled dextrogyre peptide which selectively inhibits the c-Jun N-terminal kinase, is a powerful neuroprotectant in mouse models of middle cerebral artery occlusion (MCAo) with delayed intracerebroventricular injection. We aimed to determine whether this neuroprotection could also be achieved by intravenous injection of XG-102, which is a more feasible approach for future use in stroke patients. We also tested the compatibility of the compound with recombinant tissue plasminogen activator (rtPA), commonly used for intravenous thrombolysis and known to enhance excitotoxicity. Methods: Male ICR-CD1 mice were subjected to a 30-min-suture MCAo. XG-102 was injected intravenously in a single dose, 6 h after ischemia. Hippocampal slice cultures were subjected to oxygen (5%) and glucose (1 m M) deprivation for 30 min. rtPA was added after ischemia and before XG-102 administration, both in vitro and in vivo. Results: The lowest intravenous dose achieving neuroprotection was 0.0003 mg/kg, which reduced the infarct volume after 48 h from 62 ± 19 mm 3 (n = 18) for the vehicle-treated group to 18 ± 9 mm 3 (n = 5, p < 0.01). The behavioral outcome was also significantly improved at two doses. Addition of rtPA after ischemia enhanced the ischemic damage both in vitro and in vivo, but XG-102 was still able to induce a significant neuroprotection. Conclusions: A single intravenous administration of XG-102 several hours after ischemia induces a powerful neuroprotection. XG-102 protects from ischemic damage in the presence of rtPA. The feasibility of systemic administration of this promising compound and its compatibility with rtPA are important steps for its development as a drug candidate in ischemic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NXY-059 for Acute Ischemic Stroke
Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660 · cited 1×
“Despite high expectations for new therapeutic compounds, clinical trials in the acute phase of stroke yielded very disappointing results so far. Recently, after a promising phase-3 trial (SAINT-I) showing a mild but significant benefit on neurological outcome [”
BackgroundA peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658
Self-citationCell-Permeable Peptide Inhibitors of JNK
Bonny, C., Oberson, A., Negri, S., Sauser, C., & Schorderet, D. F. (2001) · Diabetes · doi:10.2337/diabetes.50.1.77 · Cited by 571
Self-citation
Cited by
Rose, B. A., Force, T., & Wang, Y. (2010) · Physiological Reviews · doi:10.1152/physrev.00054.2009 · Cited by 723
Nuclear and cytosolic JNK signalling in neurons
Coffey, E. T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3729 · Cited by 338
c-Jun N-terminal kinase (JNK) signaling: Recent advances and challenges
Bogoyevitch, M. A., Ngoei, K. R. W., Zhao, T. T., Yeap, Y. Y. C., & Ng, D. C. H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.002 · Cited by 323
Neuroprotective Role of Lactate after Cerebral Ischemia
Berthet, C., Lei, H., Thevenet, J., Gruetter, R., Magistretti, P. J., & Hirt, L. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.97 · Cited by 281
Self-citationChiquet, C., Aptel, F., Creuzot-Garcher, C., Berrod, J.-P., Kodjikian, L., Massin, P., Deloche, C., Perino, J., Kirwan, B.-A., de Brouwer, S., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.10.012 · Cited by 52
Metadata
- Authors
- Wiegler, K., Bonny, C., Coquoz, D., & Hirt, L.
- Venue
- Cerebrovascular Diseases
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 26
- Issue
- 4
- Pages
- 360-366
- ISSN
- 1015-9770 (ISSN-L)
- 1421-9786
- OpenAlex
- W2015182670
- Cited by
- 53
- References
- 3
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The JNK Inhibitor XG-102 Protects from Ischemic Damage with Delayed Intravenous Administration Also in the Presence of Recombinant Tissue Plasminogen Activator. https://app.cochat.ai/papers/10.1159/000151639
- The paper
- Wiegler, K., Bonny, C., Coquoz, D., & Hirt, L. (2008). The JNK Inhibitor XG-102 Protects from Ischemic Damage with Delayed Intravenous Administration Also in the Presence of Recombinant Tissue Plasminogen Activator. Cerebrovascular Diseases. https://doi.org/10.1159/000151639
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.